公开(公告)号：EP1861379A1

公开(公告)日：2007-12-05

申请号：EP06723722.2

申请日：2006-03-20

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： REHWINKEL, Hartmut ,  SCHÄCKE, Heike ,  BÄURLE, Stefan ,  BERGER, Markus ,  REHWINKEL, Hartmut ,  MENGEL, Anne ,  KROLIKIEWICZ, Konrad ,  BUCHMANN, Bernd ,  SCHMEES, Norbert

IPC分类号： C07D239/74 ,  C07D239/80 ,  C07D309/36 ,  C07D217/24 ,  C07D209/46 ,  C07D209/34 ,  C07D237/32 ,  C07D215/38 ,  C07C69/732 ,  C07C69/734 ,  C07D215/22 ,  A61K31/365 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/473

CPC分类号： C07D237/30 ,  C07D215/227 ,  C07D215/38 ,  C07D239/74

摘要： The invention relates to tetrahydronaphthalene derivatives of general formula (I), to a method for their production and to their use as anti-inflammatory agents.

公开(公告)号：EP1791807A1

公开(公告)日：2007-06-06

申请号：EP05782883.2

申请日：2005-08-29

申请人： Pfizer Products Incorporated

发明人： CLAFFEY, Michelle Marie Pfizer Global R & D ,  FLIRI, Anton Franz Josef Pfizer Global R & D ,  GALLASCHUN, Randall James Pfizer Global R & D ,  O'DONNELL, Christopher John Pfizer Global R & D

IPC分类号： C07C217/90 ,  C07D239/74 ,  C07D261/20 ,  C07D307/87 ,  C07D333/50 ,  C07D333/72 ,  A61K31/135 ,  A61K31/39 ,  A61K31/343 ,  A61K31/47 ,  A61K31/381

CPC分类号： A61K31/137 ,  A61K31/277 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/423 ,  A61K31/428 ,  C07C217/90 ,  C07C317/32 ,  C07C323/32 ,  C07C2602/08 ,  C07D239/74 ,  C07D261/20 ,  C07D307/87 ,  C07D333/50 ,  C07D333/72

摘要： This invention is directed to compounds of formula la, lb or Ic and to pharmaceutical compositions thereof: formula (Ia), formula (Ib), formula (Ic) or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated with 5HT receptors, including obesity, attention deficit disorder, migraine, depression, epilepsy, anxiety, Alzheimer's disease, withdrawal from drug abuse, pain, schizophrenia, stress-related disorders, panic disorder, sleep disorders, phobias, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, stress-induced gastrointestinal dysfunction, stress-induced cardiovascular dysfunction, and sexual dysfunction.

摘要翻译： 本发明涉及式Ia，Ib或Ic的化合物及其药物组合物：式（Ia），式（Ib），式（Ic）或其前药以及药学上可接受的载体，其中R基团在 规范; 并且其中虚线表示可选的双键。 本发明还涉及治疗，诊断和预防与5HT受体有关的中枢神经系统疾病的方法，包括肥胖症，注意力缺陷障碍，偏头痛，抑郁症，癫痫症，焦虑症，阿尔茨海默病，戒断药物滥用， 疼痛，精神分裂症，压力相关障碍，惊恐障碍，睡眠障碍，恐怖症，强迫症，创伤后压力综合征，免疫系统抑制，压力诱导的胃肠功能障碍，压力诱发的心血管功能障碍和性功能障碍。

公开(公告)号：EP1689387A2

公开(公告)日：2006-08-16

申请号：EP04811726.1

申请日：2004-11-18

申请人： Array Biopharma, Inc.

发明人： WALLACE, Eli ,  YANG, Hong, Woon ,  LYSSIKATOS, Joseph, P.

IPC分类号： A61K31/40 ,  A61K31/495 ,  A61K31/415 ,  C07D209/44 ,  C07D237/26 ,  C07D231/56

CPC分类号： C07D209/46 ,  C07D213/80 ,  C07D213/82 ,  C07D215/48 ,  C07D231/56 ,  C07D237/24 ,  C07D237/28 ,  C07D237/32 ,  C07D239/74 ,  C07D401/04 ,  C07D401/06 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04

摘要： Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R20, R21, and R22 are as defined in the specification. Such compounds are MFK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

公开(公告)号：EP1638945A1

公开(公告)日：2006-03-29

申请号：EP04740190.6

申请日：2004-06-22

申请人： Schering Aktiengesellschaft

发明人： BERGER, Markus ,  BÄURLE, Stefan ,  REHWINKEL, Hartmut ,  SCHMEES, Norbert ,  SCHÄCKE, Heike ,  LEHMANN, Manfred ,  KROLIKIEWICZ, Konrad ,  SCHOTTELIUS, Arndt, J., B. ,  NGUYEN, Duy ,  MENGEL, Anne ,  JAROCH, Stefan

IPC分类号： C07D237/30 ,  C07D239/74 ,  C07D277/64 ,  C07D241/42 ,  C07D471/04 ,  C07D237/28 ,  C07D231/56 ,  C07D209/34 ,  C07D235/06 ,  C07D209/46 ,  C07D209/08 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/416 ,  A61K31/4184

CPC分类号： C07D209/46 ,  C07D209/08 ,  C07D209/34 ,  C07D231/56 ,  C07D235/06 ,  C07D237/28 ,  C07D237/30 ,  C07D239/74 ,  C07D241/42 ,  C07D277/64 ,  C07D471/04

摘要： The invention relates to pentanol derivatives of general formula (I), which are substituted by quinazoline, quinoxaline, cinnoline, indazole, phthalazine, naphthyridine, benzothiazole, dihydroindolone, dihydroisoindolone, benzimidazole, or indole, a method for the production thereof, and the use thereof as anti-inflammatory agents.

公开(公告)号：EP1568695A1

公开(公告)日：2005-08-31

申请号：EP04030302.6

申请日：2004-12-21

申请人： Korea Institute of Science and Technology

发明人： Lee, Yong Sup ,  Lee, Jae Yeol ,  Rhim, Hyeowhon

IPC分类号： C07D239/84 ,  C07D239/74 ,  A61K31/517 ,  A61P9/10 ,  A61P9/12

CPC分类号： C07D239/74 ,  C07D239/84

摘要： The present invention relates to 3,4-dihydroquinazoline derivatives as T-type calcium channel blockers and a method of preparing the same. The present invention further relates to a composition comprising the same. The composition comprising the 3,4-dihydroquinazoline derivatives of the present invention can be effectively used for preventing and treating angina pectoris, high blood pressure, myocardial disease, pain and epilepsy by blocking the T-type calcium channel.

摘要翻译： 本发明涉及3,4-二氢喹唑啉衍生物作为T-型钙通道阻断剂和其制备的方法。 本发明还涉及包含其的组合物。 包含本发明的3,4-二氢喹唑啉衍生物的组合物可以有效地用于通过阻断T型钙通道防治心绞痛，高血压，心肌病，疼痛和癫痫。

公开(公告)号：EP1430038A1

公开(公告)日：2004-06-23

申请号：EP02767320.1

申请日：2002-08-05

申请人： Ciba Specialty Chemicals Holding Inc.

发明人： RAVICHANDRAN, Ramanathan ,  PASTOR, Stephen, Daniel ,  JUDD, Deborah ,  BABIARZ, Joseph, Edmund ,  NAUGHTON, Andrew, Brian ,  WOOD, Mervin, Gale ,  DEBELLIS, Anthony, David ,  XIONG, Rong ,  DETLEFSEN, Robert, Edward ,  SUHADOLNIK, Joseph

IPC分类号： C07D265/22

CPC分类号： C07D239/91 ,  C07D239/74 ,  C07D239/86 ,  C07D249/20 ,  C07D265/22 ,  C07D405/04

摘要： The present invention relates to novel ultraviolet light absorbers of the benzoxazinone, oxanilide, benzylidene malonate, quinazoline and benzotriazole classes. The invention also relates to polymer and photographic compositions stabilized against the deleterious effects of light induced degradation which comprise the novel ultraviolet light absorbers.

公开(公告)号：EP1401451A2

公开(公告)日：2004-03-31

申请号：EP02758236.0

申请日：2002-06-14

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： BEERLI, René ,  TOMMASI, Ruben, Alberto ,  WEILER, Sven ,  WIDLER, Leo

IPC分类号： A61K31/517 ,  A61P5/18 ,  A61P19/10 ,  C07D239/82

CPC分类号： C07D401/06 ,  C07D213/88 ,  C07D239/74 ,  C07D239/78 ,  C07D239/82 ,  C07D239/84 ,  C07D265/36 ,  C07D401/12 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D417/06

摘要： Use of compound of formula (I), wherein (a) is (b) or (c) and wherein the symbols are as defined, or a pharmaceutically-acceptable and-cleavable ester, or acid addition salt thereof, for the preparation of a medicament for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.

公开(公告)号：EP0832073B1

公开(公告)日：2002-01-16

申请号：EP96917174.3

申请日：1996-06-04

申请人： Sugen, Inc.

发明人： TANG, Peng, Cho ,  McMAHON, Gerald

IPC分类号： C07D239/74 ,  C07D413/04 ,  A61K31/505

CPC分类号： C07D239/74

摘要： The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities. The present invention also provides pharmaceutical compositions and methods for inhibiting cell proliferation of differentiation and related disorders. Examples of such disorders include cancers, blood vessel proliferative disorders, psoriasis, hyperimmune response and fibrotic disorders. Example ofother disorders include the HER2 disorders, EGF disorders, IGFR disorders, PDGFR disorders, met disorders, SrC disorders, and KDR/FLK-1 disorders described herein. It is to be understood that compounds which are effective for diseases related to one TK will also likely be effective for diseases related to other TK's, especially those from the same family. Thus, for example, compounds shown to have good effect against Her2 are likely to also have good effect against other members of the Her family, i.e., EGFR, Her3,and Her4.

公开(公告)号：EP1105378A1

公开(公告)日：2001-06-13

申请号：EP99943800.5

申请日：1999-08-20

申请人： Parker Hughes Institute

发明人： Liu, Xing-Ping ,  Cetkovic, Marina ,  Uckun, Fatih, M. ,  Malaviya, Ravi

IPC分类号： C07D239/94 ,  A61P35/02 ,  A61P37/06 ,  A61K31/505

CPC分类号： A61K31/00 ,  A61K31/505 ,  A61K31/517 ,  C07D239/74 ,  C07D239/94

摘要： The invention provides novel JAK-3 inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are useful to treat or prevent autoimmune diseases, inflammation, and transplant rejection. The invention also provides pharmaceutical compositions comprising compounds of the invention, as well as therapeutic methods for their use.

公开(公告)号：EP1102750A1

公开(公告)日：2001-05-30

申请号：EP99936810.3

申请日：1999-07-29

申请人： AstraZeneca AB

发明人： BROWN, Dearg Sutherland ,  BROWN, George Robert

IPC分类号： C07D213/82 ,  C07D241/44 ,  C07D215/48 ,  C07D261/18 ,  C07D277/68 ,  C07D239/74 ,  C07D333/38 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D213/81 ,  A61K31/44 ,  A61K31/47 ,  A61K31/495

CPC分类号： C07D213/81 ,  C07D213/82 ,  C07D215/48 ,  C07D239/74 ,  C07D241/44 ,  C07D261/18 ,  C07D277/68 ,  C07D333/38 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12

摘要： The invention concerns amide derivatives of formula (I) wherein R3 is (1-6C)alkyl or halogeno; Q1 is heteroaryl which is optionally substituted with 1, 2, 3, or 4 substituents such as hydroxy, halogeno, trifluoromethyl, (1-6C)alkyl, (1-6C)alkoxy, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, hydroxy-(2-6C)alkoxy, amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, aryl, heteroaryl and heterocyclyl; p is 0-2 and R2 is a substituent such as hydroxy and halogeno; q is 0-4; and Q2 includes optionally substituted aryl, cycloalkyl, heteroaryl and heterocyclyl; or pharmaceutically-acceptable salts or in vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.